Betaxolol
Betaxolol, Betoptic, Kerledex (betaxolol) is a small molecule pharmaceutical. Betaxolol was first approved as Betoptic on 1985-08-30. It is used to treat hypertension and open-angle glaucoma in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. In addition, it is known to target beta-2 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Betaxolol, Betoptic (discontinued: Betaxolol, Kerlone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Betaxolol hydrochloride
Betaxolol hydrochloride
+
Chlorthalidone
Betaxolol hydrochloride
+
Pilocarpine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BETOPTIC PILO | Alcon Research | N-020619 DISCN | 1997-04-17 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| betaxolol | ANDA | 2022-05-23 |
| betaxolol hydrochloride | ANDA | 2024-04-30 |
| betoptic | 2006-10-30 | |
| betoptic pilo | 2006-06-19 | |
| betoptic s | New Drug Application | 2024-07-01 |
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AB: Beta blocking agents, selective
— C07AB05: Betaxolol
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01ED: Beta blocking agents, antiglaucoma preparations and miotics
— S01ED02: Betaxolol
— S01ED52: Betaxolol, combinations
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 4 | — | 4 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 3 | — | 3 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | 3 | — | 3 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 2 | — | 2 | 4 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 3 | — | — | 3 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | — | 2 | — | — | 2 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | — | 2 | — | — | 2 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | — | — | — | — | 1 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 1 | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Betaxolol |
| INN | betaxolol |
| Description | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent and a sympatholytic agent. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 63659-18-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL423 |
| ChEBI ID | 3082 |
| PubChem CID | 2369 |
| DrugBank | DB00195 |
| UNII ID | O0ZR1R6RZ2 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Betaxolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,639 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
916 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use